Patents by Inventor Robert Zand

Robert Zand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Radiosensitizer Formulations and Methods for Use
    Publication number: 20100035952
    Abstract: The present invention provides radiosensitizer compositions, in controlled-release formulations or other acceptable formulations, particularly nitrohistidine radiosensitizer compositions, which may be administered by any suitable means including oral, intravenous, arterial infusion, intraperitoneal, intramuscular, subcutaneous, surgical, and topical. Optionally, radiosensitizer compositions may be formulated with other agents, including chemotherapy agents and agents that provide a synergistic radiosensitizing effect. Methods of potentiating radiotherapy cancer treatment of cancers in humans, particularly of astrocytomas, are also presented, wherein a radiosensitizer composition is administered and radiotherapy is directed to the site of the tumor. Chemotherapy regimens may also be used as adjuvant therapy.
    Type: Application
    Filed: September 24, 2009
    Publication date: February 11, 2010
    Inventors: Richard H. Matthews, Nuran Ercal, Robert Zand
  • Radiosensitizer formulations and methods for use
    Patent number: 7608612
    Abstract: The present invention provides radiosensitizer compositions, in controlled-release formulations or other acceptable formulations, particularly nitrohistidine radiosensitizer compositions, which may be administered by any suitable means including oral, intravenous, arterial infusion, intraperitoneal, intramuscular, subcutaneous, surgical, and topical. Optionally, radiosensitizer compositions may be formulated with other agents, including chemotherapy agents and agents that provide a synergistic radiosensitizing effect. Methods of potentiating radiotherapy cancer treatment of cancers in humans, particularly of astrocytomas, are also presented, wherein a radiosensitizer composition is administered and radiotherapy is directed to the site of the tumor. Chemotherapy regimens may also be used as adjuvant therapy.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: October 27, 2009
    Inventors: Richard H. Matthews, Nuran Ercal, Robert Zand
  • Electroactive materials
    Patent number: 5142045
    Abstract: Novel polymers containing 6,6,6-tricyclic moieties pendant from the polymer backbone, their novel monomers, and novel conductive polymers formed by doping the novel polymers with an electron acceptor compound. The novel polymers are easily synthesized, are soluble in various solvents, and are more stable than conductive polymers having the tricyclics as repeating units in the polymer backbone. A preferred tricyclic is phenothiazine.
    Type: Grant
    Filed: May 27, 1988
    Date of Patent: August 25, 1992
    Assignees: Aisin Seiki Kabushiki Kaisha, The Regents of the University of Michigan
    Inventors: Robert Zand, Shinji Nezu, Selim Kusefoglu